AACR data continue to support confidence in AVA6000

Lighthouse | 10 April 2024

Share this note

  • Interim data from the Phase I trial of AVA6000, a peptide drug conjugate, have been presented in a poster at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego. These are the latest findings in 42 patients (as of 11 March data cutoff), including some from the seventh and final cohort in the three-weekly dosing arm. Importantly, the data reaffirm prior observations that AVA6000 is selectively activated at the target tumour site, resulting in lower toxicities than standard doxorubicin, and leading to anti-tumour effects in cancers with over-expression of FAP and which are sensitive to doxorubicin monotherapy.
  • Updated safety data for AVA6000 continue to show a lower incidence of severe (Grade 3 and 4) treatment-related adverse events (AEs) compared to doxorubicin. This observation is consistent when analysing all AEs, including mild to moderate. Two dose-limiting toxicities (DLTs) were observed in earlier cohorts; of note the patient with Grade 2 cardiac failure at 120mg/m2 had a significant risk of cardiovascular disease and an expert cardiovascular review concluded it was not anthracycline related. In each DLT case, the cohort was expanded and the dose escalated to the next cohort. More recently, there were no DLTs at the seventh dose level of 385 mg/m2 (equivalent to c 3.5x the normal doxorubicin dose) and a Safety Data Monitoring Committee (SDMC) concluded that this dose was safe. Overall, most compelling was the fact that no maximum tolerated dose was achieved.
  • The poster also includes an overview of the best overall response, stratified by FAP status. In the 15 patients with cancer types categorised as high FAP (based on a literature review), there were: 2 partial responses (≥30% decrease in the sum of diameters of the target lesion) of which 1 is confirmed and 1 is unconfirmed and both are ongoing; and 3 minor responses (a 10-29% decrease), with two ongoing. Ongoing patients could potentially see improved responses in the future. Seven patients had stable disease for ≥16 weeks. Recall that patients in this trial had been heavily pretreated (median of three prior regimens) and most patients would typically not be offered an anthracycline like doxorubicin. Hence responses were not expected.
  • Given the favourable safety in the three-weekly dosing arm, coupled with PK/PD modelling, patients are currently being enrolled in a two-weekly safety study, with three patients already dosed in the first cohort (160mg/m2) in the US. Approvals have also been granted to start the trial in the UK. First cohort safety data should be reviewed by the SDMC by the end of April.

Trinity Delta view: The proprietary pre|CISION platform is key to Avacta’s investment case, hence updated data that continue to support key hypotheses for AVA6000 are reassuring. Future efficacy data from studies planned to start in H224 will be key, and could also help to more broadly validate pre|CISION. The recent £31.1m fundraise (March 2024 Lighthouse), which provides a cash runway of c 24 months ie into early 2026, will be used to advance the therapeutics pipeline, in particular AVA6000, and should cover a number of value inflection points in AVA6000’s development. Our valuation and forecasts are currently suspended; our last published valuation was £672m (equivalent to 237p/share).


10 April 2024

Market Cap£195.13m
Primary exchangeAIM
Company CodeAVCT
Corporate clientYes

Company description

Avacta owns two novel technology platforms: Affimer and pre|CISION. Affimer proteins are antibody mimetics being developed as diagnostic reagents and oncology therapeutics. pre|CISION improves potency and reduces toxicity of cancer drugs by only activating them inside the tumour. Successful clinical trials would be transformative for Avacta.


Lala Gregorek
+44 (0) 20 3637 5043

Philippa Gardner
+44 (0) 20 3637 5042


Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2024 Trinity Delta Research Limited. All rights reserved.